S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:DOCS

Doximity - DOCS Price Target & Analyst Ratings

$34.78
+0.79 (+2.32%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$33.64
$35.31
50-Day Range
$24.00
$34.94
52-Week Range
$22.91
$68.01
Volume
2.13 million shs
Average Volume
3.13 million shs
Market Capitalization
$6.69 billion
P/E Ratio
53.51
Dividend Yield
N/A
Price Target
$42.94

Doximity Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 15 Analyst Ratings

Consensus Analyst Price Target

$42.94
23.45% Upside
High Prediction$60.00
Average Prediction$42.94
Low Prediction$29.00
TypeCurrent
12/2/21 to 12/2/22
1 Month Ago
11/2/21 to 11/2/22
3 Months Ago
9/3/21 to 9/3/22
1 Year Ago
12/2/20 to 12/2/21
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
7 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.94$44.29$46.57$74.67
Predicted Upside23.45% Upside10.55% Upside10.49% Upside2.22% Upside
Get Doximity Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.


DOCS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DOCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Doximity Stock vs. The Competition

TypeDoximityMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside23.45% Upside569.70% Upside11.38% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
44
51.76%
Underperform Votes
41
48.24%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$28.00 ➝ $32.00+21.53%
11/11/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$38.00 ➝ $44.00+67.11%
11/11/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$39.00 ➝ $35.00+32.93%
10/13/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
9/15/2022KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Weight ➝ Sector Weight
9/7/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$35.00+8.76%
8/8/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Close
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$47.00 ➝ $42.00+12.57%
8/5/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$43.00 ➝ $29.00-28.06%
7/29/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingInitiates
5/18/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$78.00 ➝ $46.00+56.89%
5/18/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$70.00 ➝ $52.00+77.35%
5/18/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$70.00 ➝ $45.00+53.48%
5/18/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$72.00 ➝ $56.00+91.00%
5/18/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$55.00 ➝ $35.00+3.64%
5/18/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$60.00 ➝ $40.00+18.45%
5/18/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$68.00 ➝ $45.00+33.25%
12/14/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jackson Ader
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underweight$70.00 ➝ $60.00+7.76%
11/10/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$65.00 ➝ $72.00-5.89%
7/19/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Daniels
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 12/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












DOCS Price Target - Frequently Asked Questions

What is Doximity's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Doximity stock is Hold based on the current 2 sell ratings, 4 hold ratings and 9 buy ratings for DOCS. The average twelve-month price prediction for Doximity is $42.94 with a high price target of $60.00 and a low price target of $29.00. Learn more on DOCS's analyst rating history.

Do Wall Street analysts like Doximity more than its competitors?

Analysts like Doximity less than other Medical companies. The consensus rating for Doximity is Hold while the average consensus rating for medical companies is Buy. Learn more on how DOCS compares to other companies.

Do MarketBeat users like Doximity more than its competitors?

MarketBeat users like Doximity less than other Medical companies. 51.76% of MarketBeat users gave Doximity an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Does Doximity's stock price have much upside?

According to analysts, Doximity's stock has a predicted upside of 23.02% based on their 12-month price targets.

What analysts cover Doximity?

Doximity has been rated by BTIG Research, Evercore ISI, KeyCorp, Piper Sandler, Truist Financial, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DOCS) was last updated on 12/2/2022 by MarketBeat.com Staff